Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Keep Inspiring

Don’t let your disease define you

Approval of First CAR T-Cell Therapy for Relapsed/Refractory MCL to Change How Patients are Treated 'Forever and for the Better'

August 4th 2020, 10:00pm

Article

“The FDA approval of (Tecartus) will change the way we treat patients with relapsed MCL forever and for the better,” said Dr. Michael Wang.

5 Recent FDA Approvals Patients with Cancer May Have Missed

August 3rd 2020, 7:00pm

Article

The Food and Drug Administration has had a busy summer, approving new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.

No 'One Great Answer' When it Comes to What Rights Those Affected By Cancer Have When Returning to Work Amid COVID-19

July 29th 2020, 7:00pm

Video

There are some job protected options for patients with cancer, survivors and caregivers to consider when it comes to returning to work during the COVID-19 pandemic. But, as one cancer rights attorney notes, there are many challenges to those options.

FDA Approves First CAR T-Cell Therapy, Tecartus, for Relapsed or Refractory Mantle Cell Lymphoma

July 24th 2020, 10:44pm

Article

The FDA’s approval of Tecartus for adults with relapsed or refractory mantle cell lymphoma (MCL) is based on data that showed that the CAR T-cell therapy induced a response in 87% of patients.

Several Leading Cancer Organizations Urge US to Reconsider Withdrawing from the World Health Organization

July 22nd 2020, 1:50am

Article

Patients with cancer have been encouraged to reach out to legislators and share their personal stories and advocate for why they think continued funding is important to further cancer research.

Expert Advises Genetic Profiling in MCL Can Be a Useful Tool in Treating The Disease

July 7th 2020, 10:57pm

Article

“We learned from previous prospective studies (that) using chemoimmunotherapy for those patients with TP53 aberrations, the survival data compared with others that do not harbor this mutation are much less favorable,” said Dr. Jia Ruan.

Analysis Identifies Predictors of Survival in Older Patients With Mantle Cell Lymphoma

July 7th 2020, 5:58pm

Article

“It is important to note that the data predates the widespread use of BTK inhibitors and even cellular therapies such as CAR T-cell therapy, specifically,” Dr. Reem Karmali said in an interview. “And so, it doesn't reliably reflect the potential advancements and survival that we've been able to achieve with these novel targeted therapies.”

Cancer Survivors Reflect on a Day of Celebration and Inspiration

June 8th 2020, 10:07pm

Article

To commemorate National Cancer Survivors Day on June 7, CURE® invited its readers to share their encouraging stories of survival.

Pharmacologic Data Supports Use of Novel CAR T-Cell Therapy in Patients With Poor-Risk Mantle Cell Lymphoma

May 31st 2020, 8:06pm

Article

“Altogether, this pharmacological data supports the concept of CAR T-cell therapy being able to overcome MCL disease with poor risk factors,” said lead study author Dr. Luhua (Michael) Wang.

Revlimid and Rituxan Combo 'Another Potential Option' For Patients With Mantle Cell Lymphoma

May 30th 2020, 6:00pm

Video

“We now have second and third generation cousins of thalidomide that are very useful. So, lenalidomide in combination with rituximab is an effective therapy for mantle cell lymphoma that voids some of these adverse events that I’m talking about,” said Dr. Ian Flinn. Hear more about this treatment in his interview with CURE®.